Effects of CAR T-cell therapy on thinking skills in young patients with blood cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the cognitive aftereffects of CAR T-cell therapy in children and young adults aged 5-35 with relapsed or refractory leukemia or lymphoma. Researchers will assess how this innovative treatment may impact memory, attention, and other cognitive functions over a 12-month period. Participants will undergo cognitive testing either at home or at designated clinical sites, and their medical histories will be reviewed to gather comprehensive data. The study also involves caregivers who will provide additional insights into the participants' cognitive performance.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Participants with disease

  * Participants are diagnosed with relapsed/refractory leukemias or lymphomas, and are scheduled to receive CAR T-cell treatment in one of the enrolling sites
  * For participants enrolled on a CAR T-cell treatment protocol, data sharing for the purposes of this study must be allowed.
  * Age \>= 5 and \<=35 years old
  * Participant must have an eligible caregiver (informant) who is willing to complete assessments about the participant of this study
  * Participants (\<18 years, or \>=18 years if needed) must have an eligible caregiver to assist with setting up an appropriate test environment for the remote evaluations
  * Participant must be able to speak and understand English or Spanish
  * Participants must have access to a computer or tablet with a camera and an internet connection
  * Participant or parent/guardian must be able to understand and willing to sign a written consent document
* Caregivers (informants)

  * Participants must be able to speak and read in English or Spanish
  * Participants who are caregivers for participants with disease addressed above
  * Age \>= 18 years old
  * Participants must have access to a computer or tablet
  * Participants (of children \<18 years, or \>18 years if needed) must be willing to help set up an appropriate test environment for the remote evaluations
  * Participant is able to understand and willing to sign a written consent document

EXCLUSION CRITERIA:

-Participants with disease who have a pre-existing global intellectual disability (e.g., Down Syndrome)

Where it's running

• Children s Hospital of Los Angeles
  Los Angeles, California, United States Recruiting
• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting
• Seattle Children s Hospital
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Pamela L Wolters, Ph.D. — National Cancer Institute (NCI)
• Study coordinator: NCI Ped LeukemiaLymph Cell Tx Tm
• Email: ncilltct@mail.nih.gov
• Phone: (240) 760-6970

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prophylactic use of Tocilizumab to prevent complications after CAR-T therapy

  This study is testing if giving Tocilizumab before or during CAR-T therapy can help prevent serious side effects like cytokine release syndrome and neurotoxicity in patients with B-cell cancers.

  Recruiting Phase 2 Insel Gruppe AG, University Hospital Bern · Bern, Canton of Bern · NCT06430736

• CAR-T therapy outcomes and quality of life in older adults with B‑cell lymphoma

  This project will see how CAR‑T therapy affects older adults (age 60+) with relapsed or refractory B‑cell lymphomas, focusing on daily function and quality of life while they receive standard care.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York · NCT04300998

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• CD19/CD22 CAR-T as first-line consolidation for follicular lymphoma

  This trial tests whether CAR-T cells targeting CD19 and CD22 can be used as a first-line consolidation therapy for people with follicular lymphoma to see if it improves outcomes.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07587840

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.